表紙
市場調査レポート

Promius Pharma, LLC:製品パイプライン分析

Promius Pharma, LLC - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 321985
出版日 ページ情報 英文 48 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。
Back to Top
Promius Pharma, LLC:製品パイプライン分析 Promius Pharma, LLC - Product Pipeline Review - 2016
出版日: 2016年03月22日 ページ情報: 英文 48 Pages
概要

Promius Pharma, LLCは米国に本社を置くファーマシューティカル企業です。皮膚ケア製品など皮膚疾患の分野に対する製品の開発・販売を行っています。

当レポートでは、Promius Pharma, LLC における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Promius Pharma, LLC の基本情報

  • Promius Pharma, LLC の概要
  • 主要情報
  • 企業情報

Promius Pharma, LLC :R&Dの概要

  • 主な治療範囲

Promius Pharma, LLC :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Promius Pharma, LLC :パイプライン製品の概況

  • 後期段階にあるパイプライン製品
    • 第3相の製品/併用療法モダリティ
  • 臨床段階にあるパイプライン製品
    • 第2相の製品/併用療法モダリティ

Promius Pharma, LLC :薬剤プロファイル

  • DFD-01
  • ACT-01
  • DFD-06

Promius Pharma, LLC :パイプライン分析

  • 投与経路別
  • 分子タイプ別

Promius Pharma, LLC :最新のパイプライン情報

Promius Pharma, LLC :開発が休止されたプロジェクト

Promius Pharma, LLC :本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07993CDB

Summary

Global Markets Direct's, 'Promius Pharma, LLC - Product Pipeline Review - 2016', provides an overview of the Promius Pharma, LLC's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Promius Pharma, LLC, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Promius Pharma, LLC
  • The report provides overview of Promius Pharma, LLC including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Promius Pharma, LLC's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Promius Pharma, LLC's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Promius Pharma, LLC's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Promius Pharma, LLC
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Promius Pharma, LLC's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Promius Pharma, LLC Snapshot
    • Promius Pharma, LLC Overview
    • Key Information
    • Key Facts
  • Promius Pharma, LLC - Research and Development Overview
    • Key Therapeutic Areas
  • Promius Pharma, LLC - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Promius Pharma, LLC - Pipeline Products Glance
    • Promius Pharma, LLC - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Promius Pharma, LLC - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Promius Pharma, LLC - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Promius Pharma, LLC - Drug Profiles
    • DFD-01
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DFN-11
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tetracycline MR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DFD-06
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DFD-10
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DFN-02
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ACT-01
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • celecoxib
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DFN-10
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DFN-15
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DFN-14
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DFN-19
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DFD-04
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DFD-05
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DFD-08
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules 1 for Epilepsy
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules 1 for Parkinson's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules 2 for Epilepsy
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules 2 for Parkinson's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules 3 for Epilepsy
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules 3 for Parkinson's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules 4 for Epilepsy
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules 4 for Parkinson's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Promius Pharma, LLC - Pipeline Analysis
    • Promius Pharma, LLC - Pipeline Products by Target
    • Promius Pharma, LLC - Pipeline Products by Route of Administration
    • Promius Pharma, LLC - Pipeline Products by Molecule Type
    • Promius Pharma, LLC - Pipeline Products by Mechanism of Action
  • Promius Pharma, LLC - Recent Pipeline Updates
  • Promius Pharma, LLC - Dormant Projects
  • Promius Pharma, LLC - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Promius Pharma, LLC, Key Information
  • Promius Pharma, LLC, Key Facts
  • Promius Pharma, LLC - Pipeline by Indication, 2016
  • Promius Pharma, LLC - Pipeline by Stage of Development, 2016
  • Promius Pharma, LLC - Monotherapy Products in Pipeline, 2016
  • Promius Pharma, LLC - Pre-Registration, 2016
  • Promius Pharma, LLC - Phase III, 2016
  • Promius Pharma, LLC - Phase II, 2016
  • Promius Pharma, LLC - Phase I, 2016
  • Promius Pharma, LLC - Preclinical, 2016
  • Promius Pharma, LLC - Pipeline by Target, 2016
  • Promius Pharma, LLC - Pipeline by Route of Administration, 2016
  • Promius Pharma, LLC - Pipeline by Molecule Type, 2016
  • Promius Pharma, LLC - Pipeline Products by Mechanism of Action, 2016
  • Promius Pharma, LLC - Recent Pipeline Updates, 2016
  • Promius Pharma, LLC - Dormant Developmental Projects,2016

List of Figures

  • Promius Pharma, LLC - Pipeline by Indication, 2016
  • Promius Pharma, LLC - Pipeline by Stage of Development, 2016
  • Promius Pharma, LLC - Monotherapy Products in Pipeline, 2016
  • Promius Pharma, LLC - Pipeline by Target, 2016
  • Promius Pharma, LLC - Pipeline by Route of Administration, 2016
  • Promius Pharma, LLC - Pipeline by Molecule Type, 2016
  • Promius Pharma, LLC - Pipeline Products by Mechanism of Action, 2016
Back to Top